Abstract 4757
Background
The challenge faced by the cancer patient is access to care and for the health system, thenon-availability of qualified personnel. Besides financial issues, patients face challenges of finding a cancer center. Governments are keen to offer universal health coverage but are in need of sustainable systems. A novel healthcare delivery system was designed and has been operational in several states of India.
Methods
General duty medical officers and nurses from government district hospitals were trained in oncology for one month. Various administrative reforms, restructuring and techno-mentoring (constant, 24x7, mentorship using WhatsAppR, Telephonic communication, regular continuing medical education) were used to create a system of health care delivery in oncology. The drug distribution system was changed to include essential oncology drugs.
Results
A district cancer care programme has been initiated in six states of India, involving 157 hospitals constituting about 20 % of the nation. The hospital has a nodal cancer unit, with nodal cancer officer and nurse in charge to deliver cancer services, such as counselling at all stages of care, assistance in diagnostics, (which may vary from biopsy to scan to tumor markers), follow up care, palliative care, end of life care and, most importantly, chemotherapy. A patient from the district has a choice of conitnuum of care at local hospital to which he is used. He can visit more frequently with no cost involved. This system change and empowerment has allowed the government to bring care closer to the facility and help patients gain access. A satisfaction survey done amongst patients shows there is a strong willingness to follow in districts.This is saving thousand of families from impoverishment. The creation of a system of cancer care delivery has led to other states following this example. From one state it has gone to six states,(population coverage of around 300 million).
Conclusions
Primary care physicians can be effectively empowered to offer specialised cancer care in government-run facilities. This duplicable, sustainable model (Pendharkar model) using existing human resources can be used by many countries fighting with shortages of personnel and access issues.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dinesh Pendharkar.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract